Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

2.525 +0.015 (+0.60%)
Streaming Delayed Price Updated: 3:08 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cathie Wood's Ark Invest Sells Coinbase Shares As Bitcoin Drops Below Key $62K Level ↗
On Monday, Cathie Wood-led Ark Invest made some significant trades, with Coinbase Global Inc. (NASDAQ:COIN) taking the spotlight. This comes amidst a turbulent market scenario, particularly for... 
Via Benzinga
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
From Absci Corporation
Via GlobeNewswire
News headline image
The Analyst Verdict: Absci In The Eyes Of 6 Experts ↗
 
Via Benzinga
News headline image
6 Analysts Assess Absci: What You Need To Know ↗
 
Via Benzinga
News headline image
Absci: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week ↗
The global 
Via Talk Markets
News headline image
Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares ↗
On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir 
Via Benzinga
News headline image
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In ↗
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
The Analyst Landscape: 4 Takes On Absci ↗
 
Via Benzinga
News headline image
Why Absci (ABSI) Shares Are Falling ↗
Absci shares are trading lower by 9.4% Wednesday afternoon. The company announced an offering of 16.7 million shares at $4.50 per share. 
Via Benzinga
News headline image
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs ↗
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024 ↗
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
News headline image
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
News headline image
All 7 AI Category Portfolios Continued To Decline This Week ↗
All 54 AI stocks in the 7 AI category portfolios dropped this week, down 8.4%, on average, making it clear that the surge in the AI sector that began back on October 31st is over. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
From Absci Corporation
Via GlobeNewswire
News headline image
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
News headline image
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
News headline image
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023 ↗
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗
Grand View Research says the global 
Via Talk Markets
News headline image
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Pricing of Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after 
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.